1. BHF Cardiovascular Research Centre, University of Glasgow, UK (C.A., K.F.D., M.C.P., P.S.J., J.J.V.M.).
2. Department of Clinical Pharmacy and Pharmacology (H.J.L.H.), University Medical Center Groningen, University of Groningen, The Netherlands.
3. Department of Cardiology (R.A.d.B., K.D.), University Medical Center Groningen, University of Groningen, The Netherlands.
4. Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
5. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.).
6. Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City (M.N.K.).
7. The George Institute for Global Health, University of New South Wales, Sydney, Australia (M.N.K.).
8. Universidad Nacional de Córdoba, Argentina (F.A.M.).
9. Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
10. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA (M.S.S.).
11. Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark (M. Schou).
12. Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA (S.D.S., M.V.).
13. Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Ontario, Canada (S.V.).
14. Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., A.M.L., M. Sjöstrand).